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Summary
Background: Varicella is often considered to be a benign disease of childhood. In fact, varicella
is associated with serious complications and mortality even among healthy individuals.
Discussion: Although the course of varicella can be uncomplicated, it can also be associated
with serious complications such as pneumonia, fluid and electrolyte disturbances, skin and soft
tissue infections and central nervous system disturbances. Worldwide studies have confirmed
the high frequency of disease as well as the resultant morbidity, mortality and medical resource
use. A quadrivalent vaccine is now available in certain countries to protect against measles,
mumps, rubella and varicella (MMRV). Countries that have initiated routine vaccination pro-
grams have reported substantial reductions in morbidity and mortality as well as improved
health outcomes. The MMRV vaccine facilitates coverage against all four diseases, and would be
expected to improve compliance as well as coverage of varicella.
Conclusions: Universal vaccination programs with MMRV should be considered as a way to reduce
the medical and economic impact of varicella. The MMRV vaccine provides a means to achieve
universal coverage.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
Varicella is a common childhood disease that is considered
primarily an inconvenient but uncomplicated rite of pas-
sage. In reality, the seriousness of varicella should not be
underestimated because complications, and even death,
can occur in otherwise healthy children.1,2 Healthy children
under 12 years of age account for almost 50% of fatalities.3
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Varicella can have potentially devastating consequences
such as pneumonia, fluid and electrolyte disturbances,
skin and soft tissue infections and central nervous system
disease.4- 6 Although adults account for a much smaller
percentage of cases, varicella-associated mortality and
complication rates are even higher among adults, and have
increased over time.3,6,7
Symptomatic treatment and antiviral agents can be
used to manage varicella, but have a limited effect on the
disease course in normal children. Prevention rather than
treatment has therefore been recommended as the optimal
approach to the disease.4,8 Universal vaccination appears
to be the best way to reduce the incidence of varicella,4,6,9
and achieving this will also protect those who are not eli-
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gible for vaccination, such as immunocompromised persons
and infants.6
Sharp decreases in morbidity and mortality rates from
varicella have been attributed to implementation of vacci-
nation programs in the U.S.10,11 U.S. death records showed
that during the 25 years (1970–1994) prior to introduction
of the varicella vaccine in 1995, 90 deaths per year were
reported, primarily among children (84%).6 More recently,
8 varicella-related deaths were described in the U.S.
between January 2003 and June 2004.1
A U.S. case-control study reported that 87% of vacci-
nated children had mild varicella compared with 45% of
unvaccinated children (p < 0.001).9 A five-year survey
found that the incidence of varicella and hospitalizations
declined approximately 85% in three U.S. communities
with high vaccination rates. 11 Analytical models designed
for France and Germany found that complication rates
and medical resource use decreased substantially with
high rates of coverage.12,13 Despite this, varicella vaccina-
tion rates of approximately 85% are still being reported
among 19- to 35-month old children, indicating that more
widespread vaccination is necessary.11,14 Of even greater
concern, some countries do not perceive varicella vac-
cination as a high priority despite the preponderance of
evidence showing that it is a major public health issue.4
The need for universal vaccination to eradicate vari-
cella means that a new quadrivalent measles, mumps,
rubella, varicella (MMRV) vaccine may become a key fac-
tor to ensure the successful implementation of routine
childhood varicella vaccination in European and other
countries.10,15- 17 This article will describe the epidemiology
of varicella, its complications, the worldwide experience
with vaccination programs, and the potential for the MMRV
vaccine to facilitate universal coverage rates in Europe.
Epidemiology and clinical manifestations of
varicella
The clinical course of varicella typically involves an in-
cubation period of 8 to 21 days, followed by a phase
during which fever and malaise occur. A rash then appears,
characterized by macules, papules, vesicles, pustules, and
scabs. After 7 to 14 days, shedding of crusts can be
expected.18,19
The prevalence of varicella throughout Europe is high,
albeit variable. In France, between 1991 and 1995,4,20
varicella was associated with a complication rate of 2%.
Morbidity and mortality data among non-immune per-
sons in France from 1990 to 1999 revealed death rates of
7, 104, and 5,345 per million cases depending on whether
the patient was 1 to 4 years, 25 to 34 years, or older
than 65 years of age.21 Age is a risk factor for varicella-
related mortality, with mortality rates increasing sharply
for patients over 20 years of age.6
Other data from Europe confirm this. Among 384,000
children in Italy, 20,513 cases were reported.22 Varicella-
associated morbidity increased steadily for children 0 to 4
years in age over the study period (1961 through 1996).
Seroprevalence rates in Germany have been reported as
fairly consistent, with 760,000 new cases in 1999.23,24 Ten
percent of cases occurred in persons 12 years of age or
older. Varicella-associated complications were reported in
approximately 6% of all patients, with an average of 0.1
hospital days/case. The annual rate of varicella-associated
hospitalizations was 4.1 per 100,000 persons in Spain in
1999–2000, resulting in over 11,000 hospitalizations.25 In
Catalonia, seroprevalence rates of 85% among 5 to 9 year
olds and 92% among 10 to 14 year olds were described,
with an annual hospitalization rate of 2.8 per 100,000
persons.25,26 An analysis of death certificates in England
and Wales estimated that there were 826,881 reported
cases of varicella from 1985 to 1997, and found a case
fatality rate of 9.2 per 100,000 consultations.27
In Australia, approximately 240,000 cases are reported
each year, with 1500 varicella-related hospitalizations and
10 to 20 fatalities.28,29 A cross-sectional survey found that
approximately 56% of children had varicella, while 42%
had been vaccinated.30 These data are consistent with
European data showing a high seroprevalence, low to
moderate vaccination rates, and a higher than might be
expected rate of childhood hospitalizations and deaths due
to varicella.
Complications of varicella in children can be
severe
The course of varicella is not always mild and
uncomplicated.2 Complications may include pneumonia,
fluid and electrolyte imbalances, central nervous system
disorders, bacterial skin infections, and permanent scar-
ring. The most serious complications include pneumonia,
encephalitis, cerebellar ataxia, arthritis, and Guillain-
Barré syndrome.31 Pneumonia is a common complication,
as are some of the more easily managed complications such
as skin and soft-tissue infections and fluid and electrolyte
disturbances.5 Invasive group-A β-haemolytic streptococcal
infection is also a risk in children with varicella.32 While
rare, children developed serious complications such as
necrotizing fasciitis, Reye' s syndrome and encephalitis in
the prevaccine era.
Congenital varicella syndrome is another rare yet very
serious outcome of varicella infection. The affected infant
typically experiences low birth weight, cutaneous scars,
limb hypoplasia, and ocular and neurological lesions.33 A
prospective study conducted in Germany and the United
Kingdom between 1980 and 1993 found nine cases of con-
genital varicella syndrome among 1373 women who had
varicella during the first 36 weeks of gestation.34 Only
two of these cases occurred among 472 pregnancies in
which maternal varicella occurred. The authors concluded
that while the risk of congenital varicella syndrome was
small, the sequelae were serious enough to make prenatal
diagnosis valuable, and further suggested that prevention
through vaccination would be a good option.
Finally, purpura fulminans is a life-threatening compli-
cation that can occur secondary to varicella.35 It is char-
acterized by cutaneous hemorrhage and necrosis caused
by disseminated intravascular coagulation and vascular
thrombosis.35
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The value of universal vaccination
Universal vaccination of young children, combined with
immunization of unvaccinated adolescents, is expected to
dramatically reduce both the number of cases of varicella
and its complications.6,36 The U.S. experience has shown
that since the varicella vaccine has been available, there
have been fewer cases of varicella and fewer complications
and hospitalizations. The effectiveness of the Oka/Merck
varicella vaccine was shown in a case-control study of 339
cases from 20 pediatric practices.9 This study, conducted
between March 1997 and June 2003, found that the vaccine
was 97% effective against typical disease (p < 0.001) the
first year after vaccination, and 84% effective (p = 0.003)
in years 2 to 8 after vaccination, for an overall effective-
ness of 87% (p < 0.001). Varicella was significantly more
severe in unvaccinated children (p < 0.001). Among 122
“breakthrough” cases that occurred in vaccinated children,
106 (87%), had mild varicella, compared with 98 of 217
(45%) in unvaccinated children (p < 0.001).
The declining incidence of varicella in three U.S. com-
munities (1995 to 2000) was documented in a population-
based surveillance study (Figure 1).11 During the study
period, the number of varicella cases declined 71%, 84%,
and 79% in each of the three communities, with vaccine
coverage of 82%, 74%, and 84% respectively. Accordingly,
hospitalizations declined from 2.7 to 4.2 per 100,000 pop-
ulation in 1995 to 1.5 per 100,000 in 2000. These real-life
results illustrate how universal vaccination has reduced the
incidence of varicella as well as hospitalization rates in the
U.S.
The importance of vaccination against varicella has
been recognized in studies worldwide that have highlighted
the positive impact of vaccination on improved health out-
comes and greater cost-effectiveness. A prospective study
of 683 children in Spain found complications in 14.8% (n
= 101) of the children, with 5 requiring hospitalization.37
Minor complications increased the disease duration as well
as the cost. Medical visits and prescription drugs (€ 32.5
per patient) accounted for the majority of the direct
costs, while workdays missed accounted for the greatest
indirect costs (€ 62.6 per patient). The authors conceded
that vaccination costs could exceed the direct costs, but
Figure 1 A population-based surveillance study demonstrated the declining incidence of varicella in three U.S. communities (1995–2000).11
concluded that universal vaccination was economical when
indirect costs were taken into account.
A cost-benefit analysis based on an epidemiological
model and a prospective observational study of 1832
cases in France demonstrated the value of combining
varicella vaccination with measles-mumps-rubella (MMR)
vaccination.12 The highest rates of vaccination coverage
were associated with the greatest benefits, including the
lowest incidence of varicella and it complications and the
greatest cost savings. The model showed that when 80%
of children were vaccinated, both the vaccinated and non-
vaccinated populations benefited. When 70% or fewer were
vaccinated, the risk of complications increased, particu-
larly among non-vaccinated adults, a population that has
a higher risk of complications. When vaccination coverage
was higher than 40%, a reduction in direct medical costs
associated with varicella was observed for all parame-
ters, with much greater savings when indirect costs were
considered.
A model examining the economic value of routine vari-
cella vaccination in Germany assessed the benefits, costs,
and cost-effectiveness over a 30-year period.13 Assuming
a coverage rate of 85% and a vaccine efficacy rate of
86%, routine childhood vaccination could prevent approxi-
mately 611,000 varicella cases and more than 4700 major
complications each year in Germany. Average yearly cost
savings were estimated at € 51.3 million. The benefit-cost
ratio was greatest for adolescent vaccination, but this
approach provided inferior medical outcomes. The authors
concluded that routine childhood varicella vaccination was
a highly efficient and cost-saving strategy to decrease the
burden of varicella.
An Australian cost-effectiveness study simulated di-
rect costs and complications of varicella over a 30-year
period.38 This simulation found that the infant vaccina-
tion program was more cost-effective than adolescent or
catch-up programs An infant program could avert 4.4 mil-
lion cases, 13,500 hospitalizations, and 30 deaths over 30
years. These results were relatively insensitive to coverage
rates of 50% to 80%. These results are in line with European
results, where universal infant vaccination would have a
positive impact on costs, medical resource used, morbidity,
and mortality.
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Assuming no impact of vaccination on Zoster, varicella
vaccination was estimated to cost $ 45,000, $ 51,000, and
$ 18,000 per life-year gained from the health payer' s per-
spective for infants, infants with catch-up campaigns, and
preteen programs, respectively.39 Mass infant varicella vac-
cination was estimated to be highly cost saving in Canada
from a societal perspective. The cost-effectiveness of in-
fant vaccination also will be influenced by the relationship
between varicella and zoster, which is not known at this
time
Barriers to vaccination
The goals of varicella immunization are to prevent the
disease and its complications in children and especially
in immunocompromised patients, pregnant women, and
adults. Varicella vaccination has clearly decreased the
number of varicella deaths in all age groups in the U.S.
(Figure 2).40 The estimated vaccination coverage in the
U.S. has increased, but can the vaccine be even more
widely used? A study examined records of 178,616 chil-
dren (19 to 36 months old) to estimate varicella vaccine
coverage in the U.S. between 1997 and 2004. Cover-
age rates increased from 26% in 1997 to 87% in 2004.41
Under-vaccinated populations included those living in the
Midwest, living in a household with more than one child,
living in a non-metropolitan area, living below the poverty
line, having a mother who did not have a college de-
gree, and having public providers; some of these factors
were more important than others. The authors concluded
that varicella vaccine uptake has been steadily improv-
ing, although additional opportunities exist for improved
coverage.
An Australian study examined parental attitude to vari-
cella vaccination programs.30 The most common reasons
parents gave for non-vaccination were that the child had
previous varicella infection (34.5%), the parent was un-
aware of the vaccine (12.3%), the vaccine was not included
in the schedule (11.7%), the cost of the vaccine was high
(8.9%), they planned to get the child vaccinated but had
not done so yet (7.2%), or that the vaccine was unavailable
when other childhood immunizations were given (6.4%).
Figure 2 The number of varicella-related deaths has decreased in all age groups between 1990 and 2001, following the introduction of the
vaccine in 1995.40
The most common reasons for non-vaccination in Italy
included perceptions that varicella was a mild disease and
that immunity obtained from childhood disease endures
throughout adolescence and adulthood.42 There was a
general misperception that breakthrough disease may be
common following the vaccination. It was felt that stronger
guidelines could address the need for varicella vaccination
as a school entry requirement.
Attitudes towards varicella vaccine vary between coun-
tries. A recent survey conducted in France, Italy, and
Germany examined physician (n = 865) and parental (n
= 3440) attitudes towards varicella vaccination, to better
understand why widespread vaccination is not practiced.42
While most physicians understood the seriousness of vari-
cella, more than 80% of parents believed that varicella was
harmless. Most German physicians advocated varicella vac-
cination in children (67.7%), compared with approximately
50% of French and 39% of Italian physicians. Physicians
advocated for adolescent or adult vaccination in 63%, 23%,
and 31% of cases, respectively, in Germany, France, and
Italy. More than 80% of the time, parents followed physi-
cian vaccine recommendations. Sick-leave rates were 33%
in Germany, 56% in France, and 74% in Italy. Only 22.5%
to 36% of vaccinations were given concurrently with other
vaccines, principally the MMR vaccine (60.8% to 88.3%).
The authors theorized that acceptance could be enhanced
by co-administration of varicella vaccine with MMR.
Physicians play a crucial role in the acceptance of any
vaccination. As such, physicians must know that while
the disease is often mild, there are severe complica-
tions that include death, morbidity and socio-economic
consequences. Physicians in Europe are accustomed to
concomitant administration of vaccinations, making con-
current administration of varicella with MMR a good way to
go forward.
MMRV vaccine
Universal vaccination policies for varicella in the U.S. have
led to a decline in disease when coverage exceeded 70%.43
The continuation of existing vaccine policies is expected
to lead to further reductions in varicella-associated mor-
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Figure 3 The estimated vaccination coverage in the U.S. is shown here. MMR coverage is greater than varicella coverage, suggesting that
MMRV would serve to increase overall varicella immunization.49
bidity and mortality.43 A quadrivalent vaccine offers many
benefits for implementing universal vaccination. Adding
varicella to MMR decreases the number as well as the
overall burden of injections. This decreased burden would
be expected to enhance compliance and lead to increased
rates of immunization. Most importantly, an effective, well
tolerated quadrivalent vaccine for MMRV has the potential
to achieve universal immunization (Figure 3).4
Efficacy and tolerability of MMRV
The Oka/Merck varicella vaccine is highly immunogenic
and effective against clinical disease.4 The MMRV vaccine
was studied in 812 children who were 12 months to 3.5
years old.44 Children received either: (1) MMRV (ProQuad®)
and placebo versus MMR (II) and varicella-zoster vaccine
(Varivax®), or (2) diphtheria-tetanus-acellular pertussis
vaccine and oral polio vaccine with MMRV or MMRII plus
varicella-zoster vaccine. More than 95% of all children in
this study seroconvert for measles, mumps, rubella and
varicella, independent of the vaccine regimen.
An open label, multicenter study administered
diphtheria-tetanus-acellular pertussis vaccine with com-
bined Haemophilus influenzae type b conjugate-hepatitis
B vaccines (Comvax®) plus either MMRV (ProQuad®) (con-
comitantly or 42 days later) or MMR (II) and varicella
vaccination (Varivax®) (42 days later) to 1915 healthy chil-
dren 12 to 15 months old.17 Concomitant administration
of MMRV and the other vaccines was effective and well
tolerated, with varicella antibody response rates of 89.7%
to 98.9% of those achieved when the varicella vaccine was
given alone. A potentially age-related lower antibody re-
sponse to the pertussis vaccine was noted. A total of 76.9%
to 80.6% of children in all groups experienced at least one
systemic adverse event, with injection site adverse events
being the most common. More injection site adverse events
were noted among MMRV-vaccinated children who received
concomitant administration of other vaccines as opposed to
additional vaccination 42 days later. Patients who received
MMRV reported a significantly higher incidence of fever
than those who received MMR plus varicella, although most
cases were mild and thought to be associated with concur-
rent conditions such as infection. The authors concluded
that the results supported use of MMRV with the other
childhood vaccinations.
In a prospective study conducted in the U.S., children
4 to 6 years old who had already received one dose of M-
M-RII or M-M-RII plus Varivax were given MMRV (ProQuad®)
with placebo, (n = 399), M-M-RII and placebo (n=195),
or M-M-RII and Varivax®(n = 205).16 Noninferiority was
demonstrated in antibody response to measles, mumps and
rubella between children who received MMRV and children
who received M-M-RII. The same was true for varicella
antibody response in children receiving MMRV and Varivax.
Postvaccination seropositivity rates for antibodies against
all four viruses were approximately 100% in all cases. Small
increases in measles, mumps and rubella antibody titers
were observed. Injection site reactions were the most
common adverse experiences, occurring in 51.3% to 56.2%
of children in each group. Systemic adverse experiences
occurred in 54.7% to 60% of children in each group. MMRV
was thought to be appropriate in place of a second dose of
M-M-RII or M-M-RII plus Varivax, resulting in good efficacy
and tolerability.
A trial of 3928 healthy children 12–23 months of age
demonstrated the consistency of three different lots of
MMRV (ProQuad®) by evaluating the safety and immuno-
genicity following a single dose and comparing the response
with a control group of children who received M-M-RII plus
Varivax®.45 Immune responses were similar among children
who received each of the 3 lots of MMRV, and between the
MMRV and control groups. In addition, one-year antibody
persistence rates were >95% for each lot of MMRV. A
greater incidence of fever was observed with MMRV than
the control group (39.1% vs. 33.1%, p = 0.001), although the
overall incidence of adverse events was comparable. MMRV
was felt to have comparable immunogenicity and tolerabil-
ity to M-M-RII plus Varivax®, with long-term persistence of
antibodies expected.
A multicenter study randomized 480 healthy 12–23
month old children to receive either MMRV (ProQuad®) plus
placebo and a second dose of MMRV (ProQuad®) 90 days
later, or M-M-RII plus Varivax®.46 The safety and immuno-
genicity of each regimen was evaluated. Rash (5.9% vs.
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1.9%) and fever (27.7% vs. 18.7%) were more commonly
reported following the first dose of MMRV compared with
M-M-RII plus Varivax; the incidence of other adverse events
was similar between the two groups. Response rates >90%
were observed to each vaccine in both groups. The geomet-
ric mean titers to measles and mumps were significantly
higher following the first dose of MMRV compared with M-
M-RII plus Varivax. The two treatments were considered to
be similar in terms of both tolerability and immunogenicity.
Until recently, the majority of children in the U.S.
received a single-dose of varicella vaccine. During an out-
break, the effectiveness of a single dose in children under
13 years old is approximately 95%, making it important
to evaluate whether of a second dose might be of use,
especially if the goal is to end endemic disease in the
U.S.47 The Advisory Committee for Immunization Practices
in the U.S. has recently recommended that a second dose
of varicella vaccine be administered at 4–6 years of age,
the same time as the second dose of MMR vaccine, in order
to increase the protection provided by the vaccine and
decrease varicella outbreaks.48
Conclusions
The complications of varicella can be severe. Univer-
sal vaccination can dramatically reduce the incidence of
varicella, varicella-associated complications, hospitaliza-
tion rates and fatalities. MMRV is an immunogenic and
well tolerated vaccination that induces immune responses
similarly to its component vaccines M-M-RII and Varivax
and is compatible with other childhood vaccinations. As a
quadrivalent vaccine, MMRV has the potential to improve
compliance and coverage rates for varicella vaccination.
Worldwide data are available to allow physicians and ad-
ministrators to weigh the costs and benefits of vaccination.
It is now a matter of public policy for each national govern-
ment to determine how best to use MMRV to improve local
health outcomes.
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